Similar Items: Pharmacometrics of dolutegravir and tenofovir: a quantitative approach to characterise drug-drug interactions, pharmacogenetics and optimise treatment
- Pharmacometric modelling to inform and improve TB and HIV treatment: Focus on drug-drug interactions and neglected populations
- Pharmacogenomics and pharmacokinetics of dolutegravir and tenofovir in Southern Africans living with HIV
- Pharmacogenetics of Tenofovir (Alafenamide or Disoproxil Fumarate Prodrug) Renal Toxicity in HIV positive Black Southern Africans
- Pharmacokinetics, pharmacogenetics and optimisation of treatment with non-nucleoside reverse transcriptase inhibitors in HIV-infected African children
- Addressing challenges in the treatment of tuberculosis and tuberculosis meningitis: a pharmacometric approach
- Efavirenz pharmacogenetics and metabolic toxicity in black South Africans
Author: Denti, Paolo
- Pharmacometric modelling to inform and improve TB and HIV treatment: Focus on drug-drug interactions and neglected populations
- Pharmacokinetics, pharmacogenetics and optimisation of treatment with non-nucleoside reverse transcriptase inhibitors in HIV-infected African children
- Population pharmacokinetic modelling to optimise treatment for children with Rifampicin-resistant TB and HIV
- Population pharmacokinetic and pharmacodynamic modelling to improve tuberculosis treatment
- A scoping review on the use of telerehabilitation in physiotherapy in low and middle income countries
- Advancing tuberculosis treatment through pharmacometric modeling of drug exposure and biomarkers